Literature DB >> 25614625

Exposure of neutralizing epitopes in the carboxyl-terminal domain of TcdB is altered by a proximal hypervariable region.

Jason L Larabee1, Aleze Krumholz1, Jonathan J Hunt1, Jordi M Lanis1, Jimmy D Ballard2.   

Abstract

The sequence, activity, and antigenicity of TcdB varies between different strains of Clostridium difficile. As a result, ribotype-specific forms of TcdB exhibit different toxicities and are not strongly cross-neutralized. Using a combination of biochemical and immunological approaches, we compared two important variants of TcdB (TcdB012 and TcdB027) to identify the mechanisms through which sequence differences alter epitopes and activity of the toxin. These analyses led to the discovery of a critical variation in the 1753-1851 (B2') region of TcdB, which affects the exposure of neutralizing epitopes in the toxin. Sequence comparisons found that the B2' region exhibits only 77% identity and is the most variable sequence between the two forms of TcdB. A combination of biochemical, analytical, and mutagenesis experiments revealed that the B2' region promotes protein-protein interactions. These interactions appear to shield neutralizing epitopes that would otherwise be exposed in the toxin, an event found to be less prominent in TcdB012 due to sequence differences in the 1773-1780 and 1791-1798 regions of the B2' domain. When the carboxyl-terminal domains of TcdB012 and TcdB027 are swapped, neutralization experiments suggest that the amino terminus of TcdB interacts with the B2' region and impacts the exposure of neutralizing epitopes in the carboxyl terminus. Collectively, these data suggest that variations in the B2' region affect protein-protein interactions within TcdB and that these interactions influence the exposure of neutralizing epitopes.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Antibody; Bacterial Pathogenesis; Bacterial Toxin; Clostridium difficile; Infectious Disease; Ribotype 027; TcdB; Toxin

Mesh:

Substances:

Year:  2015        PMID: 25614625      PMCID: PMC4358121          DOI: 10.1074/jbc.M114.612184

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Structural organization of the functional domains of Clostridium difficile toxins A and B.

Authors:  Rory N Pruitt; Melissa G Chambers; Kenneth K-S Ng; Melanie D Ohi; D Borden Lacy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

2.  Autocatalytic cleavage of Clostridium difficile toxin B.

Authors:  Jessica Reineke; Stefan Tenzer; Maja Rupnik; Andreas Koschinski; Oliver Hasselmayer; André Schrattenholz; Hansjörg Schild; Christoph von Eichel-Streiber
Journal:  Nature       Date:  2007-03-04       Impact factor: 49.962

3.  Epidemic Clostridium difficile.

Authors:  Mark H Wilcox; Jane Freeman
Journal:  N Engl J Med       Date:  2006-03-16       Impact factor: 91.245

4.  Structural determinants for membrane insertion, pore formation and translocation of Clostridium difficile toxin B.

Authors:  Selda Genisyuerek; Panagiotis Papatheodorou; Gregor Guttenberg; Rolf Schubert; Roland Benz; Klaus Aktories
Journal:  Mol Microbiol       Date:  2011-01-28       Impact factor: 3.501

5.  TcdB from hypervirulent Clostridium difficile exhibits increased efficiency of autoprocessing.

Authors:  Jordi M Lanis; Logan D Hightower; Aimee Shen; Jimmy D Ballard
Journal:  Mol Microbiol       Date:  2012-02-28       Impact factor: 3.501

6.  Clostridium difficile infection in Europe: a hospital-based survey.

Authors:  Martijn P Bauer; Daan W Notermans; Birgit H B van Benthem; Jon S Brazier; Mark H Wilcox; Maja Rupnik; Dominique L Monnet; Jaap T van Dissel; Ed J Kuijper
Journal:  Lancet       Date:  2011-01-01       Impact factor: 79.321

7.  Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile.

Authors:  Jordi M Lanis; Soumitra Barua; Jimmy D Ballard
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

Review 8.  The enterotoxicity of Clostridium difficile toxins.

Authors:  Xingmin Sun; Tor Savidge; Hanping Feng
Journal:  Toxins (Basel)       Date:  2010-07-14       Impact factor: 4.546

9.  Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium.

Authors:  Richard A Stabler; Miao He; Lisa Dawson; Melissa Martin; Esmeralda Valiente; Craig Corton; Trevor D Lawley; Mohammed Sebaihia; Michael A Quail; Graham Rose; Dale N Gerding; Maryse Gibert; Michel R Popoff; Julian Parkhill; Gordon Dougan; Brendan W Wren
Journal:  Genome Biol       Date:  2009-09-25       Impact factor: 13.583

10.  Toxin B is essential for virulence of Clostridium difficile.

Authors:  Dena Lyras; Jennifer R O'Connor; Pauline M Howarth; Susan P Sambol; Glen P Carter; Tongted Phumoonna; Rachael Poon; Vicki Adams; Gayatri Vedantam; Stuart Johnson; Dale N Gerding; Julian I Rood
Journal:  Nature       Date:  2009-03-01       Impact factor: 49.962

View more
  15 in total

1.  Deletion of a 19-Amino-Acid Region in Clostridioides difficile TcdB2 Results in Spontaneous Autoprocessing and Reduced Cell Binding and Provides a Nontoxic Immunogen for Vaccination.

Authors:  Sarah J Bland; Jason L Larabee; Tyler M Shadid; Mark L Lang; Jimmy D Ballard
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

2.  Clostridioides difficile Toxin B Activates Group 3 Innate Lymphocytes.

Authors:  Rosemary L Pope; Alisha Chitrakar; Prakash Sah; Tyler Shadid; Jimmy D Ballard; Lauren A Zenewicz
Journal:  Infect Immun       Date:  2022-04-04       Impact factor: 3.609

3.  Coordination between T helper cells, iNKT cells, and their follicular helper subsets in the humoral immune response against Clostridium difficile toxin B.

Authors:  Pragya Rampuria; Gillian A Lang; T Scott Devera; Casey Gilmore; Jimmy D Ballard; Mark L Lang
Journal:  J Leukoc Biol       Date:  2016-08-26       Impact factor: 4.962

4.  Adaptive immune constraints on C. difficile vaccination.

Authors:  Mark L Lang; Binu Shrestha
Journal:  Expert Rev Vaccines       Date:  2017-09-19       Impact factor: 5.217

5.  Cell-penetrating peptides derived from Clostridium difficile TcdB2 and a related large clostridial toxin.

Authors:  Jason L Larabee; Garrett D Hauck; Jimmy D Ballard
Journal:  J Biol Chem       Date:  2017-12-15       Impact factor: 5.157

6.  Memory B Cells Encode Neutralizing Antibody Specific for Toxin B from the Clostridium difficile Strains VPI 10463 and NAP1/BI/027 but with Superior Neutralization of VPI 10463 Toxin B.

Authors:  T Scott Devera; Gillian A Lang; Jordi M Lanis; Pragya Rampuria; Casey L Gilmore; Judith A James; Jimmy D Ballard; Mark L Lang
Journal:  Infect Immun       Date:  2015-10-26       Impact factor: 3.441

7.  Amino Acid Differences in the 1753-to-1851 Region of TcdB Influence Variations in TcdB1 and TcdB2 Cell Entry.

Authors:  Jonathan J Hunt; Jason L Larabee; Jimmy D Ballard
Journal:  mSphere       Date:  2017-08-02       Impact factor: 4.389

8.  Subtyping analysis reveals new variants and accelerated evolution of Clostridioides difficile toxin B.

Authors:  Enhui Shen; Kangli Zhu; Danyang Li; Zhenrui Pan; Yun Luo; Qiao Bian; Liuqing He; Xiaojun Song; Ying Zhen; Dazhi Jin; Liang Tao
Journal:  Commun Biol       Date:  2020-07-03

9.  Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection.

Authors:  Peng Chen; Ji Zeng; Zheng Liu; Hatim Thaker; Siyu Wang; Songhai Tian; Jie Zhang; Liang Tao; Craig B Gutierrez; Li Xing; Ralf Gerhard; Lan Huang; Min Dong; Rongsheng Jin
Journal:  Nat Commun       Date:  2021-06-18       Impact factor: 14.919

10.  Intrinsic Toxin-Derived Peptides Destabilize and Inactivate Clostridium difficile TcdB.

Authors:  Jason L Larabee; Sarah J Bland; Jonathan J Hunt; Jimmy D Ballard
Journal:  MBio       Date:  2017-05-16       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.